Imaging a glowing form of durvalumab during bronchoscopy in non-small cell lung cancer
Checks where a tagged immunotherapy drug reaches tumors in unresectable lung cancer.
Plain-language title generated from the registry record
Registry title: In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
Key facts
- Where
- Groningen, NetherlandsSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer that cannot be removed by surgery, after they have finished chemoradiotherapy. A labeled form of durvalumab is used to see where the drug reaches the tumor.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Unresectable stage III non-small cell lung cancer, confirmed by tissue or cell tests. At least one tumor or lymph node must be reachable by bronchoscopy or endobronchial ultrasound. ECOG performance status 0-2.
- Earlier treatment
- Must have finished concurrent platinum-based chemoradiotherapy and be able to receive adjuvant durvalumab as standard care.
Main reasons for not taking part
- Past infusion reactions to durvalumab, other anti-PD-L1 antibodies or other monoclonal antibodies
- A medical reason that makes bronchoscopy or endobronchial ultrasound unsafe, such as severe bleeding problems or severe breathing failure
- Medical or psychiatric conditions that stop the person from giving informed consent
- Pregnancy or breastfeeding
- An investigational drug within 30 days before the tracer is given
Read by machine on 13 November 2026.
Where in Netherlands
- Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT07653438EU 2026-526251-60-00
- Record updated
- 15 July 2026
- Original description
PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy. To do this, a small dose of a fluorescently labeled version of the immunotherapy drug durvalumab is given via an intravenous (IV) drip, after which a bronchoscopy is performed to visualize where and how much of the drug reaches the tumor and lymph nodes - before the actual durvalumab treatment starts.Read full original descriptionShow less
In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy - PulmoPrint
PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy. To do this, a small dose of a fluorescently labeled version of the immunotherapy drug durvalumab is given via an intravenous (IV) drip, after which a bronchoscopy is performed to visualize where and how much of the drug reaches the tumor and lymph nodes - before the actual durvalumab treatment starts.
Inclusion: Signed informed consent prior to participation in the study; Age ≥ 18 years; Histologically or cytologically confirmed unresectable stage III non-small cell lung cancer; Completion of concurrent platinum-based chemoradiotherapy; Eligibility for adjuvant durvalumab per standard of care; At least one tumor lesion or involved lymph node accessible by bronchoscopy or endoscopic/endobronchial ultrasound, suitable for biopsy/fine-needle aspiration (FNA) and fluorescence measurement; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Patient is considered fit to undergo a research bronchoscopy (with or without addition of endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated).
Exclusion: Use of an investigational medicinal product within 30 days prior to tracer administration; Known history of infusion reactions to durvalumab, other anti-PD-L1 antibodies, or other monoclonal antibodies, according to the patient's medical history; Contraindication for bronchoscopy or endoscopic/endobronchial ultrasound (if applicable), including severe uncorrectable coagulopathy, pre-existing severe respiratory insufficiency, or any other clinical reason as judged by the investigator; Medical or psychiatric conditions compromising the patient's ability to provide informed consent, according to the treating physician; Pregnancy or breastfeeding. A negative pregnancy test must be available for women of childbearing potential on the day of tracer administration.